Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003335 · ClinicalTrials.gov registry record · Phase 2
Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer
A Phase 2 study, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT00003335 is a Phase 2 study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 44 participants.
The verdict
NCT00003335, a Phase 2 study, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
RATIONALE: Umbilical cord blood transplantation may allow doctors to give higher doses of chemotherapy or radiation therapy and kill more cancer cells. PURPOSE: This phase II trial is studying allogeneic umbilical cord blood transplantation to see how well it works when given with chemotherapy or radiation therapy in treating patients with high-risk hematologic cancer.
Interventions
- DRUG methylprednisolone
- DRUG melphalan
- DRUG busulfan
- DRUG cyclosporine
- BIOLOGICAL anti-thymocyte globulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 1998-01 |
| Est. Completion | 2012-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003335
The ClinicalTrials.gov registry entry for NCT00003335 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which methylprednisolone is the first listed.
NCT00003335 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003335 about?
NCT00003335 is a clinical study titled "Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer". RATIONALE: Umbilical cord blood transplantation may allow doctors to give higher doses of chemotherapy or radiation therapy and kill more cancer cells. PURPOSE: This phase II trial is studying allogeneic umbilical cord blood transplantation to see how well it works when given with chemotherapy or r...
What is the current status of trial NCT00003335?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 1998-01. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00003335?
The interventions under investigation include: methylprednisolone (DRUG), melphalan (DRUG), busulfan (DRUG), cyclosporine (DRUG), anti-thymocyte globulin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003335?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.